永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

未开盘 12-31 11:46:00

2.930

+0.070

+2.45%

最高2.960	最低2.760	成交量49.34万
今开2.830	昨收2.860	日振幅6.99%
总市值18.11亿	流通市值18.11亿	总股本6.18亿
成交额143.18万	换手率0.08%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":2.93,"timestamp":1767152760562,"preClose":2.86,"halted":0,"volume":493433,"delay":0,"floatShares":618000000,"shares":618000000,"eps":-0.4051500429127423,"marketStatus":"未开盘","change":0.07,"latestTime":"12-31 11:46:00","open":2.83,"high":2.96,"low":2.76,"amount":1431801,"amplitude":0.06993,"askPrice":2.93,"askSize":4000,"bidPrice":2.87,"bidSize":8000,"shortable":0,"etf":0,"ttmEps":-0.48445807820502845,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767317400000},"marketStatusCode":0,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":2.86,"openAndCloseTimeList":[[1767144600000,1767153600000]],"volumeRatio":1.9973075657864305,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2600100700","title":"新版国家医保目录今日起实施 科伦博泰生物-B（06990）三款创新药惠及患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2600100700","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600100700?lang=zh_cn&edition=full","pubTime":"2026-01-01 09:03","pubTimestamp":1767229415,"startTime":"0","endTime":"0","summary":"在这份新目录中，科伦博泰生物-B自主研发的芦康沙妥珠单抗(佳泰莱)、西妥昔单抗N01(达泰莱)与塔戈利单抗(科泰莱)三款创新药物成功跻身其中。据悉，对于晚期三阴性乳腺癌患者及EGFR-TKI治疗失败的非小细胞肺癌患者而言，传统治疗手段往往收效甚微。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","LU0196878994.USD","159992","06990","BK1574","BK1161"],"gpt_icon":0},{"id":"2595705107","title":"打卡北京小巨人｜诺诚健华总监：中国创新药几乎成为世界创新名片","url":"https://stock-news.laohu8.com/highlight/detail?id=2595705107","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595705107?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:59","pubTimestamp":1767193140,"startTime":"0","endTime":"0","summary":"\n                                                诺诚健华企业传播执行总监陆春华表示：“中国创新药的知识产权授权给了国际的MNC公司，今年上半年的总的对外授权的总金额，已经达到了600亿美元，超过了2024年...                                                [全文]\n","market":"us","thumbnail":"https://media.bjnews.com.cn/cover/2025/12/31/5670566291698688769.jpeg?x-oss-process=image/resize,m_lfit,w_365","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2025/12/31/5670566291698688769.jpeg?x-oss-process=image/resize,m_lfit,w_365"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1767193147129723.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1767193147129723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK1574","09969","BK0239","BK1161","159992","688428","06978"],"gpt_icon":0},{"id":"2595371740","title":"西南证券：2025年创新药迎来β行情 2026年创新药行情将进入精选个股阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2595371740","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595371740?lang=zh_cn&edition=full","pubTime":"2025-12-31 11:24","pubTimestamp":1767151452,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，西南证券发布研报称，2025年初，港股企业陆续达成BD;港股创新药领先上涨;3月，《政府工作报告》提出“健全药品价格形成机制，制定创新药目录，支持创新药和医疗器械发展，A股创新药跟涨。5月随着PD1/VEGR双抗首付款12.5亿美金BD落地，创新药迎来加速上涨行情。随着三季度结束，创新药迎来高位调整。该行判断，2026年创新药板块将从普涨进入精选个股行情。2026年，该行看好医","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","600369","BK0188","BK0028","BK1574","BK1161","BK0276","06978","159992","BK0183"],"gpt_icon":0},{"id":"2600032637","title":"石药集团创新药大突破：降糖新复方、减重双靶点、降压新策略齐获临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2600032637","media":"摩熵医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600032637?lang=zh_cn&edition=full","pubTime":"2025-12-31 11:22","pubTimestamp":1767151352,"startTime":"0","endTime":"0","summary":"12月29日晚，石药集团发布公告，其三大创新药物同步获得临床试验批件，覆盖糖尿病、减重、高血压三大热门治疗领域。结语石药集团此次三大创新药同期获批临床，标志着其在代谢疾病和心血管疾病领域的研发实力已进入加速阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231112312a6e3b8f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231112312a6e3b8f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1807302812.USD","BK1191","IE0008368742.USD","IE0008369823.USD","LU1813983027.USD","HK0000165453.HKD","IE00BZ08YT58.USD","LU1008478684.HKD","LU1993786604.SGD","IE00BZ08YS42.EUR","LU2039709279.SGD","SG9999004220.SGD","BK1574","LU1951186391.HKD","BK1521","LU1226287875.USD","LU0501845795.SGD","LU0880133367.SGD","LU0326950275.SGD","LU1152091754.HKD","LU1328277881.USD","IE00B5MMRT66.SGD","LU0072913022.USD","01093","LU1226288170.HKD","LU1226288253.USD","BK1161","LU0067412154.USD","06978","LU0315179316.USD","LU1960683339.HKD","LU0140636845.USD","IE00B543WZ88.USD","IE00B031HY20.USD","LU0314109678.HKD","LU1226287792.SGD","BK1515","LU1152091168.USD","IE00BZ08YR35.GBP","LU1226287529.USD"],"gpt_icon":0},{"id":"2600701555","title":"十年深耕：中国创新药授权交易从“爆发”迈向“长红”","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701555","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600701555?lang=zh_cn&edition=full","pubTime":"2025-12-31 07:00","pubTimestamp":1767135600,"startTime":"0","endTime":"0","summary":"央视财经数据显示，截至2025年11月18日，国产创新药对外授权总金额已突破千亿美元，相较于2024年实现了翻倍式增长。三生制药、三生国健与辉瑞的合作再度刷新国内药企出海交易首付款金额的最高纪录。为适配处于不同发展阶段的企业以及不同的战略目标，我国创新药企的BD交易已形成多种模式。中国创新药BD交易的爆发式增长已形成全球可见的影响力。不过，热潮之下，BD交易能否从“爆发”走向“常态化”？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231070205a48bd4cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231070205a48bd4cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1161","06978","LU0359201885.HKD","01276","BK1574","LU1023057109.AUD","LU0359202008.SGD","LU0359201612.USD","LU2543165471.USD"],"gpt_icon":0},{"id":"2595745502","title":"券商2025年调研路线图揭晓 三大板块最受青睐","url":"https://stock-news.laohu8.com/highlight/detail?id=2595745502","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595745502?lang=zh_cn&edition=full","pubTime":"2025-12-31 05:13","pubTimestamp":1767129239,"startTime":"0","endTime":"0","summary":"随着A股2025年交易收官在即，券商调研覆盖上市公司的整体情况也逐渐清晰。数据显示，截至12月30日中国证券报记者发稿时，2025年以来已有超2800家A股上市公司接待券商调研，这意味着全市场过半上市公司均获得过券商关注；从行业分布情况看，机械设备、电子、医药生物三大板块最受关注，板块内均有超过290家上市公司接待券商调研。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1355,202512313606160991.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["BK1161","06978","BK1574","AI"],"gpt_icon":0},{"id":"2595797894","title":"安科生物：与创新药公司深度绑定提升竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2595797894","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595797894?lang=zh_cn&edition=full","pubTime":"2025-12-30 20:52","pubTimestamp":1767099136,"startTime":"0","endTime":"0","summary":"证券之星消息，安科生物12月29日在投资者关系平台上答复投资者关心的问题。公司参股的博生吉公司、阿法纳公司等创新药公司在各自领域独树一帜，具有很强的竞争力，公司在参股这些公司的同时将会与这些创新药公司深度绑定，在新药研发、新药商业化等方面积极开展合作，以提升公司业务的整体性和核心竞争力。增资并购事项属于公司重大事项，请您关注公司披露的公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000040833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0042","BK0060","06978","BK0070","BK1161","BK0239","159992","300009"],"gpt_icon":0},{"id":"2595792596","title":"恒瑞医药六款创新药获临床试验批件，肿瘤管线再扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2595792596","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595792596?lang=zh_cn&edition=full","pubTime":"2025-12-30 20:26","pubTimestamp":1767097566,"startTime":"0","endTime":"0","summary":"中访网数据 江苏恒瑞医药股份有限公司及其子公司近日宣布，其自主研发及引进的六款抗肿瘤新药已获得国家药品监督管理局颁发的药物临床试验批准通知书，即将进入临床研究阶段。此次获批的药品包括SHR-4375注射液、阿得贝利单抗注射液、SHR-8068注射液、贝伐珠单抗注射液、HRS-4642注射液及注射用SHR-9839，将联合开展一项针对晚期实体肿瘤患者的Ib/II期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251230/31904557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU0359201885.HKD","LU2097828474.EUR","LU2097828805.USD","LU1655091616.SGD","LU1255011170.USD","LU1064131003.USD","LU1328615791.USD","LU2488822045.USD","LU2148510915.USD","BK1161","LU2097828557.USD","LU1781817850.SGD","LU0405327148.USD","LU1146622755.USD","LU0405327494.USD","600276","LU0359201612.USD","BK0196","LU2580892862.HKD","LU0359202008.SGD","LU1997245094.SGD","LU2289578879.USD","BK0239","BK0060","LU1969619763.USD","LU2097828714.EUR","LU1064130708.USD","LU1580142542.USD","LU1997245177.USD","BK0188","LU2097828631.EUR","01276","BK1191","BK0183","LU1820825898.SGD","LU1997244956.HKD","LU2328871848.SGD","LU2580892789.USD","BK1574","BK0012","06978","LU2543165471.USD","159992","LU2495084118.USD","BK0028","LU1023057109.AUD"],"gpt_icon":0},{"id":"2595796611","title":"引领中国创新药全球多中心同步临床开发新实践——访和誉医药董事长徐耀昌","url":"https://stock-news.laohu8.com/highlight/detail?id=2595796611","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595796611?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:22","pubTimestamp":1767090149,"startTime":"0","endTime":"0","summary":"近日，和誉医药（02256.HK）自主研发的一类新药贝捷迈（盐酸匹米替尼胶囊）获国家药品监督管理局批准上市，填补了国内腱鞘巨细胞瘤（TGCT）系统疗法的临床空白。《经济参考报》记者走进和誉医药，探寻在这场里程碑式的突破背后，和誉医药董事长兼CEO徐耀昌博士带领团队，用科学坚守与务实创新，书写了中国医药产业高质量发展的“生动答卷”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512303605811750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","06978","LU2476274720.SGD","09939","IE00B543WZ88.USD","02256","LU2476274308.USD","BK1515","LU2778985437.USD","IE00B5MMRT66.SGD","LU2488822045.USD","159992","BK1161","IE00BPRC5H50.USD","BK1574"],"gpt_icon":0},{"id":"2595735795","title":"2025医药健康回眸：在进阶中创新，于规范中前行","url":"https://stock-news.laohu8.com/highlight/detail?id=2595735795","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595735795?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:06","pubTimestamp":1767089169,"startTime":"0","endTime":"0","summary":"2025年，是中国生物医药行业在挑战中坚守初心、于变局中锚定方向的一年。这一年，行业融资市场的寒意未完全消退。数据显示，2025年上半年，国内创新药企业完成134起融资，数量创近十年同期新低；一级市场公开交易笔数与总额，亦呈逐月下降趋势。所幸，寒意挡不住创新的光芒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512303605802113.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512303605802113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","GSK.UK","LU1829250122.USD","BK4585","BK4588","09939","BK4007","BK1161","BK4532","GSK","BK1515","06978"],"gpt_icon":0},{"id":"2595670427","title":"海思科(002653.SZ)：“HSK50042”、“HSK55879”创新药IND申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2595670427","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595670427?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:20","pubTimestamp":1767082829,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科 发布公告，公司子公司上海海思盛诺医药科技有限公司于近日收到国家药品监督管理局下发的《受理通知书》，涉及产品：“HSK50042”、“HSK55879”。本次申请为HSK50042片在呼吸系统疾病领域中又一新适应症的临床试验申请，有望为呼吸疾病患者提供一种高效、安全的新型治疗选择。HSK55879片是公司自主研发的具有独立知识产权的口服小分子激动剂药物，拟用于代谢系统疾病的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","06978","IND","002653","BK0033","BK0188","159992","BK1161","BK0077","BK0239","BK1574"],"gpt_icon":0},{"id":"2595604767","title":"众生药业：呼吸系统疾病领域布局RSV创新药项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2595604767","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595604767?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:00","pubTimestamp":1767081652,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)12月30日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请详细介绍下呼吸道合胞病毒创新药进度如何了众生药业回复：您好！在呼吸系统疾病领域，公司挖掘未被满足的临床需求，布局了用于治疗呼吸道合胞病毒（RSV）感染的化学小分子创新药项目，其对多种RSV病毒株的体内外抗病毒活性强、药代特性优秀、化合物毒性低。目前该项目正处于临床前研究阶段，后续将按计划有序推进项目开发工作。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000021579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002317","BK0188","159992","06978","BK0077","BK1574","BK1161"],"gpt_icon":0},{"id":"2595662547","title":"港股创新药板块午后持续走弱，昭衍新药跌超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595662547","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595662547?lang=zh_cn&edition=full","pubTime":"2025-12-30 13:15","pubTimestamp":1767071744,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月30日，港股创新药板块午后持续走弱，昭衍新药跌超7%，荣昌生物、康龙化成、歌礼制药-B跌超5%，凯莱英、诺诚健华跟跌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512303605538957.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512303605538957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","159992","BK1141","BK0216","BK1161","BK1576","06127","603127","06978"],"gpt_icon":0},{"id":"2595743929","title":"这家药企25%股份，预计卖10.86亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2595743929","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595743929?lang=zh_cn&edition=full","pubTime":"2025-12-30 10:53","pubTimestamp":1767063208,"startTime":"0","endTime":"0","summary":"此前投资南京绿叶的深圳市绿叶私募股权投资基金合伙企业决定退出，同意将所持有的南京绿叶25%股权，以约10.86亿元的对价，转让给南京信石。另外，药渡数据库数据显示，南京绿叶还占据了注射用香菇多糖75%高市场份额，2024年销售额为5282万元。2025年前三季度，国内创新药一级市场共发生324起融资事件，同比上涨5.2%；融资金额达55.1亿美元，同比大幅增长67.6%，且重要IPO事件对整体金额拉动显著。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230105544a6df5792&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230105544a6df5792&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02186","BK1606","BK1574","BK1191","BK1161","BK1583","06978"],"gpt_icon":0},{"id":"2595784432","title":"奥赛康最新公告：奥赛康药业与阿诺医药达成1类创新药AN9025项目许可引进协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2595784432","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595784432?lang=zh_cn&edition=full","pubTime":"2025-12-29 18:59","pubTimestamp":1767005993,"startTime":"0","endTime":"0","summary":"奥赛康公告称，公司子公司奥赛康药业与阿诺医药达成许可引进协议，将获得阿诺医药在研的1类创新药AN9025项目在许可区域内的开发、生产及商业化的独占权益。奥赛康药业将向阿诺医药支付与若干销售里程碑事件达成相关的付款，总计不超过11.28亿元人民币。AN9025项目为新型口服泛RAS抑制剂，用于治疗RAS突变型实体瘤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900029021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","002755","06978","BK0028","159992","BK1161","BK0239"],"gpt_icon":0},{"id":"2595789267","title":"京新药业：LP（a）降脂创新药临床I期接近尾声","url":"https://stock-news.laohu8.com/highlight/detail?id=2595789267","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595789267?lang=zh_cn&edition=full","pubTime":"2025-12-29 18:09","pubTimestamp":1767002953,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业12月29日在投资者关系平台上答复投资者关心的问题。投资者提问：京新药业的 JX2201 目前处于 I期临床末尾，临床指标是不是达到预期效果，目前公司有没有准备启动2期临床的计划。同时请问公司这款创新药在国内同行业中属于第几梯队在国际上属于什么层次？公司的LP降脂创新药临床I期接近尾声，盐酸卡利拉嗪胶囊已提交上市申请，正常推进中，具体情况敬请关注定期报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900025460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0239","BK1161","002020","159992","BK1574"],"gpt_icon":0},{"id":"2595788890","title":"海翔药业(002099.SZ)参投公司创新药NWRD06注射液完成Ⅱ期临床首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2595788890","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595788890?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:11","pubTimestamp":1766995885,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海翔药业 发布公告，公司近日收到旗下产业基金管理人北京国信中数投资管理有限公司出具的《通知函》。NWRD06注射液是目前全球首个针对肝癌特异性靶点GPC3并进入Ⅱ期临床阶段的治疗性核酸药物，其通过激活特异性T细胞免疫清除肿瘤细胞的机制具有创新性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0192","BK1574","BK0028","BK0188","002099","BK0077","BK1161","159992","BK0239","06978"],"gpt_icon":0},{"id":"2595673500","title":"国产银屑病创新药密集突破！正大天晴重磅1类新药2期临床取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2595673500","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595673500?lang=zh_cn&edition=full","pubTime":"2025-12-29 15:00","pubTimestamp":1766991624,"startTime":"0","endTime":"0","summary":"如中国生物制药于12月29日宣布，正大天晴自主研发的1类创新药TQH3906用于中重度斑块状银屑病的二期临床试验，达到主要研究终点。除了在研药物的稳步推进，国内还有多款治疗中重度斑块状银屑病的创新药已经获批上市。国产银屑病创新药的密集突破，不仅打破了此前临床治疗对进口药物的依赖，更推动我国银屑病治疗进入精准靶向的新时代。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229150230a6dbeecd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229150230a6dbeecd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1191","09926","LU2543165471.USD","01276","LU1023057109.AUD","LU0359202008.SGD","BK1574","LU0359201612.USD","LU0359201885.HKD","06978"],"gpt_icon":0},{"id":"2595206531","title":"商保创新药目录出台后：“三除外”能否跑通？会否重演国谈药进院难？","url":"https://stock-news.laohu8.com/highlight/detail?id=2595206531","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595206531?lang=zh_cn&edition=full","pubTime":"2025-12-29 11:46","pubTimestamp":1766979960,"startTime":"0","endTime":"0","summary":"自12月7日国家医保谈判结束，次日四川省即印发基本医保目录、商业健康保险创新药目录的挂网采购通知。对于首次发布的商业健康保险创新药目录，业界更为关心的，是该目录纳入的19种高值创新药接下来将如何“闯三关”，也即进院、开方、支付这三道真正的难关。　　但目前尚无明确的细则，指导“三除外”政策落地。　　商保目录出台后，“三除外”如何实现，商保创新药是否会遭遇与早年国谈药相似的进院困境？","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/money/insurance/bxyy/2025-12-29/doc-inhemqaw5053913.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxyy/2025-12-29/doc-inhemqaw5053913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1161","BK1574","159992"],"gpt_icon":0},{"id":"2595053262","title":"跨国药企发起降价潮？港股通创新药逆市走低，520880溢价高企！机构力挺国产创新药：重点关注2026年Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2595053262","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595053262?lang=zh_cn&edition=full","pubTime":"2025-12-29 11:07","pubTimestamp":1766977620,"startTime":"0","endTime":"0","summary":"12月29日，港股开市走高，恒指飘红，恒科指一度涨超2%。普涨之下，创新药板块意外走低，港股通创新药ETF盘中跌逾1.5%，权重股石药集团跌逾2%，康方生物、中国生物制药等龙头股均跌逾1%。　　不过港股通创新药ETF场内持续溢价交易，显示或有低吸资金逢跌吸筹。　　消息面，2025年年末，一场由跨国药企诺和诺德与礼来主动发起的降价潮，在政府采购平台、电商平台悄然上演，实际成交价格较半年前近乎“腰斩”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-29/doc-inhemqas7995635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","520880","159992","BK1574","06978"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.0933},{"period":"1month","weight":-0.0669},{"period":"3month","weight":-0.3356},{"period":"6month","weight":-0.0201},{"period":"1year","weight":0.2739},{"period":"ytd","weight":0.2739}],"compareEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":-0.0155},{"period":"3month","weight":-0.0607},{"period":"6month","weight":0.0717},{"period":"1year","weight":0.2777},{"period":"ytd","weight":0.2777}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括EAL和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.065686},{"month":2,"riseRate":0.6,"avgChangeRate":0.206387},{"month":3,"riseRate":0.4,"avgChangeRate":-0.092735},{"month":4,"riseRate":0.2,"avgChangeRate":-0.078794},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038349},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}